Outcome of Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in Adults: Clinical Outcome and Complications

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06702111

Enrollment

1000

Registered

2024-11-22

Start date

2024-12-31

Completion date

2030-12-31

Last updated

2024-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematopoietic Stem Cell Transplant (HSCT)

Keywords

Hematopoietic stem cell transplantation, Prognostic factors, Outcome

Brief summary

To collect baseline and outcome data relating to all bone marrow, peripheral blood, cord blood hematopoietic stem cell transplants and therapies related to hematopoietic stem cell transplantation performed in Queen Mary Hospital.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients aged 18 years or older who received allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Exclusion criteria

* participant who is unable to give informed consent in a prospective cohort.

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	5 year	Time from HSCT to death or latest follow-up
Relapse-free survival	5 years	Time from HSCT to relapse, death or latest follow-up

Countries

Hong Kong

Contacts

Primary ContactHarry HS Gill, MBBS, MD, FRCP, FRCPath

gillhsh@hku.hk+852 22555859

Outcome results